Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome - PubMed (original) (raw)

Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome

Rachel L M van der Ham et al. Diabetes Care. 2009 Jan.

Abstract

Objective: To determine whether, in accordance with observations in mouse models, high concentrations of the lipoprotein lipase inhibitors apolipoprotein (Apo) CI and ApoCIII are associated with increased triglyceride concentrations and decreased fat mass in men with the metabolic syndrome.

Research design and methods: Plasma ApoCI, ApoCIII, and triglyceride concentrations were measured in the postabsorptive state in 98 men with the metabolic syndrome. Subcutaneous and visceral fat areas were measured by 3T-magnetic resonance imaging.

Results: Triglyceride concentrations were 49% higher, and the average visceral fat area was 26% lower (both P < 0.001), in subjects with high ApoCI and ApoCIII compared with low ApoCI and ApoCIII. Subjects with either high ApoCI or ApoCIII had 16% (P < 0.05) and 18% (P < 0.01) decreased visceral fat area, respectively.

Conclusions: High concentrations of ApoCI and ApoCIII are associated with increased triglycerides and decreased visceral fat mass in men with the metabolic syndrome. These findings translate mouse studies into human pathophysiology.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Illustration of the inverse relationship of ApoCI and ApoCIII concentrations with plasma triglyceride concentration (positive, A) and with visceral adipose tissue area (negative, B). ApoCI/ApoCIII < median/mean = low, ApoCI/ApoCIII > median/mean = high. Groups: 1: low ApoCI and ApoCIII (n = 35); 2: high ApoCI/low ApoCIII (n = 21); 3: low ApoCI/high ApoCIII (n = 14); 4: high ApoCI and ApoCIII (n = 28). Triglyceride concentration: 1 vs. 3, 1 vs. 4, and 2 vs. 4: P < 0.001. 2 vs. 3: P < 0.01. Visceral adipose tissue area: low ApoCI and ApoCIII vs. high ApoCI and ApoCIII: P < 0.001.

Similar articles

Cited by

References

    1. Jong MC, Hofker MH, Havekes LM: Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484, 1999 - PubMed
    1. Berbee JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC: Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 46:297–306, 2005 - PubMed
    1. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM: The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 15:239–246, 2004 - PubMed
    1. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H, Havekes LM: Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50:2779–2785, 2001 - PubMed
    1. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ: Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 54:664–671, 2005 - PubMed

MeSH terms

Substances

LinkOut - more resources